Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3150-3157

  Rosen, Lee S ^a   Gordon, David ^a   Tchekmedyian, Simon ^a   Yanagihara, Ronald ^a   Hirsh, Vera ^a   Krzakowski, M ^a   Pawlicki, M ^a   de Souza, Paul ^a   Zheng, Ming ^a   Urbanowitz, Gladys ^a   Reitsma, Dirk ^a   Seaman, John J ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; ANEMIA; ARTICLE; BONE METASTASIS; BONE PAIN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERCALCEMIA; LUNG CANCER; MAJOR CLINICAL STUDY; MORBIDITY; MULTICENTER STUDY; NAUSEA; PATHOLOGIC FRACTURE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; SPINAL CORD COMPRESSION; VOMITING; BONE TUMOR; FEMALE; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; NEOPLASM; PATHOLOGY;

BONE NEOPLASMS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASMS; PLACEBOS;

EID: 0042914647     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.04.105     Document Type: Article

References (15)

1. Coleman RE: Skeletal complications of malignancy. Cancer 80:1588-1594, 1997
2. Bloomfield DJ: Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 16:1218-1225, 1998
3. Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 19:558-567, 2001
4. Berenson JR, Rosen LS, Howell A, et al: Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study. Cancer 91:1191-1200, 2001
5. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377-387, 2001
6. Lipton A, Small E, Saad F, et al: The new bisphosphonate, ZOMETA (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: A comparison to pamidronate. Cancer Invest 20:45-47, 2001 (abstr, suppl)
7. Cleeland CS, Ryan KM: Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore 23:129-138, 1994
8. Andersen PK, Gill RD: Cox's regression model for counting processes: A large sample study. Ann Stat 10:1100-1120, 1982
9. Cook RJ, Major P: Methodology for treatment evaluation in patients with cancer metastatic to bone. J Natl Cancer Inst 93:534-538, 2001
10. Li QH, Lagakos SW: Use of the Wei-Lin-Weissfeld method for the analysis of a recurring and a terminating event. Stat Med 16:925-940, 1997
11. Kelly PJ, Lim LL: Survival analysis for recurrent event data: An application to childhood infectious diseases. Stat Med 19:13-33, 2000
12. Berenson JR, Lichtenstein A, Porter L, et al: Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group. N Engl J Med 334:488-493, 1996
13. Hortobagyi GN, Theriault RL, Porter L, et al: Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases: Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 335:1785-1791, 1996
14. Zojer N, Keck AV, Pecherstorfer M: Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 21:389-406, 1999
15. Saad F, Gleason DM, Murray R, et al: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458-1468, 2002